Understanding the Market | AKESO rises nearly 5% to reach a new high as the first dose in the Phase III clinical trial of the Yvoxi combination therapy for IO-resistant NSCLC is completed
I'm PortAI, I can summarize articles.
AKESO's stock price rose nearly 5% in the morning session, reaching a new high of HKD 160.4, currently reported at HKD 158.7, with a transaction volume of HKD 950 million. The company announced that the Phase III clinical study of its PD-1/VEGF bispecific antibody new drug, Ivosidenib combined with Docetaxel, has completed its first administration, marking the initiation of the 7th Phase III study in the field of lung cancer. Ivosidenib is expected to reshape the treatment landscape for advanced non-small cell lung cancer
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments